Thromb Haemost 1986; 55(03): 333-337
DOI: 10.1055/s-0038-1661558
Original Article
Schattauer GmbH Stuttgart

Platelet Activation Induced by a Human Neuroblastoma Tumor Cell Line Is Reduced by Prior Administration of Ticlopidine

Eva Bastida
The Facultad de Medicina, Servicio Hemoterapia y Hemostasia, Hospital Clinico y Provincial, Universidad de Barcelona, Barcelona, Spain
,
G Escolar
The Facultad de Medicina, Servicio Hemoterapia y Hemostasia, Hospital Clinico y Provincial, Universidad de Barcelona, Barcelona, Spain
,
L Almirall
The Facultad de Medicina, Servicio Hemoterapia y Hemostasia, Hospital Clinico y Provincial, Universidad de Barcelona, Barcelona, Spain
,
A Ordinas
The Facultad de Medicina, Servicio Hemoterapia y Hemostasia, Hospital Clinico y Provincial, Universidad de Barcelona, Barcelona, Spain
› Author Affiliations
Further Information

Publication History

Received 16 September 1985

Accepted 18 March 1986

Publication Date:
26 July 2018 (online)

Preview

Summary

Ticlopidine (250 mg twice daily) was administered to human volunteers for seven days and the response of their heparinized platelet-rich plasma to SKNMC (ADP-dependent) human neuroblastoma cells was examined. The first wave of platelet aggregation, characteristic of ADP-dependent human tumor cell lines, was completely abolished but was replaced by a lag period prior to the onset of aggregation. In the Baumgartner perfusion apparatus there was a marked inhibition in the thrombus generated by the presence of SKNMC cells with a concomitant increase in the percentage of surface coverage. These results suggest that the administration of ticlopidine could be useful to prevent some of the steps of metastatic dissemination in which activated platelets may play a role.